Biodistribution and anti-tumor activities of the 131I-labeled rituximab in nude mice bearing human Burkitt’s lymphoma
- 1 August 2009
- journal article
- Published by Springer Science and Business Media LLC in Clinical Oncology and Cancer Research
- Vol. 6 (4), 256-262
- https://doi.org/10.1007/s11805-009-0256-y
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Radioimmunotherapy prevents local recurrence of colonic cancer in an experimental modelBritish Journal of Surgery, 2009
- PHARMACOKINETICS AND BIODISTRIBUTION STUDIES OF DOXORUBICIN LOADED POLY(BUTYL CYANOACRYLATE) NANOPARTICLES SYNTHESIZED BY TWO DIFFERENT TECHNIQUESBiomedical Papers, 2004
- Intraperitoneal radioimmunotherapy in treating peritoneal carcinomatosis of colon cancer in mice compared with systemic radioimmunotherapy.Cancer Science, 2003
- Labeling of monoclonal antibodies with 153Sm for potential use in radioimmunotherapy.Applied Radiation and Isotopes, 2002
- Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experienceBlood, 2000
- Multicenter Phase II Study of Iodine-131 Tositumomab for Chemotherapy-Relapsed/Refractory Low-Grade and Transformed Low-Grade B-Cell Non-Hodgkin’s LymphomasJournal of Clinical Oncology, 2000
- Dose-rate effects in targeted radiotherapyPhysics in Medicine & Biology, 1996
- CD20: a regulator of cell-cycle progression of B lymphocytesImmunology Today, 1994